Literature DB >> 15197773

Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.

Sylvia Streit1, Johannes Bange, Alexander Fichtner, Stephan Ihrler, Wolfgang Issing, Axel Ullrich.   

Abstract

Fibroblast growth factor receptors (FGFRs) have been implicated in various forms of human hyperproliferative disorders such as cancers of the cervix and bladder. We investigated the expression pattern of FGFR4 and the clinical significance of the recently identified Gly/Arg polymorphism (388) in head and neck squamous cell carcinomas (HNSCCs) of the oral cavity and the oropharynx. Sections from 104 paraffin-embedded tumors were analyzed by a restriction fragment length polymorphism-based method to determine the FGFR4 genotypes. Protein expression was investigated immunohistochemically and graded into a low, intermediate, or high degree of staining. FGFR4 expression was scored as high in 17, as intermediate in 59 and as low in 28 cases. The FGFR4 Arg388 allele was found in 59 tumors, 46 of them having heterozygous and 13 homozygous genotypes. High expression of the FGFR4 Arg388 allele was significantly associated with reduced overall survival (p = 0.032) and with an advanced tumor stage (p = 0.023), whereas expression of the FGFR4 Gly388 had no impact on disease progression. Our findings indicate that high expression of FGFR4 in connection with the Arg388 allele is associated with poor clinical outcome and support the significance of FGFR4 as a diagnostic marker and a target for therapeutic intervention in human HNSCC. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197773     DOI: 10.1002/ijc.20204

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Authors:  Marianne E Marshall; Trista K Hinz; Scott A Kono; Katherine R Singleton; Brady Bichon; Kathryn E Ware; Lindsay Marek; Barbara A Frederick; David Raben; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

3.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

Review 4.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

5.  FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.

Authors:  Wendong Yu; Shu Feng; Olga Dakhova; Chad J Creighton; Yi Cai; Jianghua Wang; Rile Li; Anna Frolov; Gustavo Ayala; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

6.  FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.

Authors:  Susana Garcia-Recio; Aatish Thennavan; Michael P East; Joel S Parker; Juan M Cejalvo; Joseph P Garay; Daniel P Hollern; Xiaping He; Kevin R Mott; Patricia Galván; Cheng Fan; Sara R Selitsky; Alisha R Coffey; David Marron; Fara Brasó-Maristany; Octavio Burgués; Joan Albanell; Federico Rojo; Ana Lluch; Eduardo Martinez de Dueñas; Jeffery M Rosen; Gary L Johnson; Lisa A Carey; Aleix Prat; Charles M Perou
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

7.  Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

Authors:  Jianghua Wang; Wendong Yu; Yi Cai; Chengxi Ren; Michael M Ittmann
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Authors:  Natacha Entz-Werle; Thomas Lavaux; Nadia Metzger; Corinne Stoetzel; Christelle Lasthaus; Perrine Marec; Chantal Kalifa; Laurence Brugieres; Hélène Pacquement; Claudine Schmitt; Marie-Dominique Tabone; Jean-Claude Gentet; Patrick Lutz; Annie Babin; Pierre Oudet; Marie Pierre Gaub; Fabienne Perrin-Schmitt
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

9.  Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns.

Authors:  G Alexe; G S Dalgin; R Ramaswamy; C Delisi; G Bhanot
Journal:  Cancer Inform       Date:  2007-02-19

10.  Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.